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Results: 519 patients were randomised (S: 261, CT-S 258) from 70 
centres in the UK, the Netherlands, Germany and Belgium. The median 
age of the patients was 63 years, 72% were male, 55% were perfor-
mance status (PS) 0, 44% PS 1, 49% had squamous cell histology, 
61% had stage I, 31% stage II, and 7% stage III disease. 12% patients 
received mitomycin/vinblastine/cisplatin, 7% mitomycin/ifosfamide/
cisplatin, 45% vinorelbine/cisplatin, 12% carboplatin/docetaxel, 
and 25% cisplatin/gemcitabine. The trial showed that neo-adjuvant 
chemotherapy was feasible (76% of patients received all 3 cycles of 
chemotherapy), resulted in a good response rate (4% CR, 45% PR), and 
appeared to cause down-staging in approximately 13% of patients. The 
use of pre-operative chemotherapy did not affect the type of surgery 
performed (lobectomy: S 61%, CT-S 66%, pneumonectomy: S 32%, 
CT-S 28%), or the post-operative complication rate. Apart from a re-
duction in ‘role physical’ (problems with work or other daily activities 
as a result of physical health) in the CT-S group at 6 months, no signiﬁ-
cant differences were observed in quality of life between the treatment 
groups. The time to (and sites of) relapse did not differ between the 
regimens, except that more patients in the CT-S group developed brain 
metastases (S 16, CT-S 31). A total of 244 patients have died (S 122, 
CT-S 122), and there is no evidence of a difference in terms of overall 
survival (HR 1.02, 95% CI 0.80, 1.31). Median, 1, 2 and 5 year sur-
vival in the S group were: 54 months, 83%, 69% and 45% respectively, 
and applying the HR to these ﬁgures gives, for the CT-S group: 53 
months, 83%, 69% and 44% respectively. Exploratory analyses showed 
no evidence that any subgroup beneﬁted signiﬁcantly more or less from 
neo-adjuvant chemotherapy.
Conclusions: This intergroup trial, which is the largest trial of neo-ad-
juvant chemotherapy in patients with resectable NSCLC, indicated that 
the addition of neo-adjuvant platinum-based chemotherapy did not lead 
to a beneﬁt in overall survival.
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Background: Building on a previous IPD meta-analysis of CT (BMJ 
1995;311:899-909) which suggested that CT may have a role in the 
treatment of NSCLC, we have carried out a new, up-to-date IPD meta-
analysis. This includes RCTs, regimens and outcomes that were not 
available in 1995. This new meta-analysis examines the role of CT in 7 
treatment comparisons. Here we report the effectiveness of supportive 
care plus CT compared with supportive care alone.
Methods: We conducted a systematic search for RCTs followed by the 
central collection, checking and re-analysis of updated IPD. Results 
from individual RCTs were combined using the stratiﬁed (by trial) log 
rank test to calculate individual and pooled hazard ratios (HRs).
Results: IPD were obtained from 15 RCTs and 2666 patients. This 
adds 6 RCTs and 1702 patients to the 1995 analyses. 11 RCTs used 
cisplatin-based CT regimens, 4 RCTs used single agent CT (etoposide, 
navelbine, gemcitabine, paclitaxel). The results show a highly sig-
niﬁcant beneﬁt of CT on survival (HR=0.78 95% Conﬁdence Interval 
0.71-0.84, p<0.000001), with an absolute beneﬁt of 8% (from 20% 
to 28%) at 12 months across all patients. There was no evidence of a 
difference in effect (p=0.69) between trials that used cisplatin-based 
regimens (11 RCTs, HR=0.76), etoposide alone (1 RCT, HR=0.87) or 
newer single agents (3 RCTs, HR=0.79) (Interaction p=0.69). There 
was no evidence that any patient subgroup deﬁned by age, sex, stage or 
histology beneﬁted more or less from CT. However, owing to differing 
underlying survival rates, the absolute beneﬁt of CT at 12 months did 
vary according to WHO/ECOG (or equivalent) performance status. PS 
0=8% (from 26% to 34%), PS 1=8% (from 18% to 26%), PS 2=5% 
(from 6% to 11%) and PS 3=4% (from 5% to 9%).
Conclusion: The results demonstrate a substantial and consistent rela-
tive beneﬁt of CT in advanced NSCLC. The effectiveness of newer 
agents such as navelbine, paclitaxel and gemcitabine (used as single 
agents) appears to be similar to that of cisplatin combined with older 
agents such as vindesine and mitomycin C. The absolute effect of CT 
varied according to performance status.
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Background: Divergent opinions exist whether patients who present 
with advanced NSCLC and performance status (PS) 2 beneﬁt from ei-
ther standard doublet chemotherapy or, due to treatment-related toxicity 
and limited survival potential, single agent therapy is more appropriate 
in these pts. 
Methods: Linear regression analysis of the data from the two largest 
phase 3 trials of de novo therapy in PS 2 pts, STELLAR 3 and 4, was 
performed to identify patient subsets that would beneﬁt from either 
doublet or singlet therapy. STELLAR 3 randomized 400 pts to either 
paclitaxel + carboplatin or paclitaxel poliglumex (PPX) + carboplatin. 
STELLAR 4 randomized 396 patients to single agent PPX or to investi-
gator choice of single agent vinorelbine or gemcitabine. Both trials had 
identical inclusion and exclusion criteria. Both arms of each trial had 
similar outcomes (HR = 0.95 and 0.97; PPX to control for STELLAR 3 
and 4, respectively). 
Results: In the univariate model, signiﬁcant predictors of compromised 
survival (p ≤ 0.01) were: albumin <3.5 gm, extrathoracic metastases 
excluding brain (ETM), hemoglobin <11 gm, weight loss >5%, LDH 
>200 IU, geographic region (US v. rest of world), any tobacco his-
tory, > 2 comorbid conditions, and disease stage (4 versus <4). In the 
multivariate model, only albumin, ETM, >2 comorbidities, and tobacco 
history were signiﬁcant (p <0.0001). Patients with none of these four 
risk factors had median survival of 473 days; survival decreased in a 
stepwise manner to 96 days in pts with all four risk factors. To analyze 
the effect of singlet v. doublet therapy on outcome, pts with three or 
